Munich, Germany, and London, UK, 13 December 2006 - Trigen, the cardiovascular drug discovery and development company, today announced the initiation of a phase I clinical study with its novel lesion-specific platelet adhesion inhibitor, PR-15, following strong efficacy displayed in pre-clinical models.
